These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
51 related articles for article (PubMed ID: 3308081)
21. Phase I clinical investigation of benzisoquinolinedione. Legha SS; Ring S; Raber M; Felder TB; Newman RA; Krakoff IH Cancer Treat Rep; 1987 Dec; 71(12):1165-9. PubMed ID: 3690526 [TBL] [Abstract][Full Text] [Related]
22. Concurrent phase I trials of intravenous interleukin 6 in solid tumor patients: reversible dose-limiting neurological toxicity. Sosman JA; Aronson FR; Sznol M; Atkins MB; Dutcher JP; Weiss GR; Isaacs RE; Margolin KA; Fisher RI; Ernest ML; Mier J; Oleksowicz L; Eckhardt JR; Levitt D; Doroshow JH Clin Cancer Res; 1997 Jan; 3(1):39-46. PubMed ID: 9815535 [TBL] [Abstract][Full Text] [Related]
23. Phase I evaluation and pharmacokinetic study of pyrazine-2-diazohydroxide administered as a single bolus intravenous injection in patients with advanced solid tumors. Supko JG; Balcerzak SP; Kraut EH Cancer Res; 1993 Oct; 53(20):4843-9. PubMed ID: 8402671 [TBL] [Abstract][Full Text] [Related]
24. Anticonvulsant usage is associated with an increased risk of procarbazine hypersensitivity reactions in patients with brain tumors. Lehmann DF; Hurteau TE; Newman N; Coyle TE Clin Pharmacol Ther; 1997 Aug; 62(2):225-9. PubMed ID: 9284859 [TBL] [Abstract][Full Text] [Related]
25. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas. Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154 [TBL] [Abstract][Full Text] [Related]
26. Phase I clinical investigation of homoharringtonine. Legha SS; Keating M; Picket S; Ajani JA; Ewer M; Bodey GP Cancer Treat Rep; 1984 Sep; 68(9):1085-91. PubMed ID: 6478448 [TBL] [Abstract][Full Text] [Related]
27. Increasing the dosage of vincristine: a clinical and pharmacokinetic study of continuous-infusion vincristine in children with central nervous system tumors. Kellie SJ; Koopmans P; Earl J; Nath C; Roebuck D; Uges DR; De Graaf SS Cancer; 2004 Jun; 100(12):2637-43. PubMed ID: 15197807 [TBL] [Abstract][Full Text] [Related]
28. [The clinical phase I study of TNP-351. The TNP-351 Research Committee]. Taguchi T; Niitani H; Furue H; Tsukagoshi S; Kanamaru R; Hasegawa K; Akazawa S; Yoneda S; Tominaga T; Sasaki T Gan To Kagaku Ryoho; 1995 Feb; 22(2):259-71. PubMed ID: 7857102 [TBL] [Abstract][Full Text] [Related]
29. Phase I study of combined pegylated liposomal doxorubicin with protracted daily topotecan for ovarian cancer. Mirchandani D; Hochster H; Hamilton A; Liebes L; Yee H; Curtin JP; Lee S; Sorich J; Dellenbaugh C; Muggia FM Clin Cancer Res; 2005 Aug; 11(16):5912-9. PubMed ID: 16115933 [TBL] [Abstract][Full Text] [Related]
30. A phase I trial of 3-hour infusions of paclitaxel (Taxol) with or without granulocyte colony-stimulating factor. Schiller JH; Storer B; Tutsch K; Arzoomanian R; Alberti D; Feierabend C; Spriggs D Semin Oncol; 1994 Oct; 21(5 Suppl 8):9-14. PubMed ID: 7524159 [TBL] [Abstract][Full Text] [Related]
31. Phase I study of carboplatin (CBDCA) in children with cancer. Bacha DM; Caparros-Sison B; Allen JA; Walker R; Tan CT Cancer Treat Rep; 1986 Jul; 70(7):865-9. PubMed ID: 3521846 [TBL] [Abstract][Full Text] [Related]
32. Topotecan combined with myeloablative doses of thiotepa and carboplatin for neuroblastoma, brain tumors, and other poor-risk solid tumors in children and young adults. Kushner BH; Cheung NK; Kramer K; Dunkel IJ; Calleja E; Boulad F Bone Marrow Transplant; 2001 Sep; 28(6):551-6. PubMed ID: 11607767 [TBL] [Abstract][Full Text] [Related]
33. Phase I Trial of G3139, a bcl-2 antisense oligonucleotide, combined with doxorubicin and cyclophosphamide in children with relapsed solid tumors: a Children's Oncology Group Study. Rheingold SR; Hogarty MD; Blaney SM; Zwiebel JA; Sauk-Schubert C; Chandula R; Krailo MD; Adamson PC; J Clin Oncol; 2007 Apr; 25(12):1512-8. PubMed ID: 17442993 [TBL] [Abstract][Full Text] [Related]
34. Activity of JM9 in advanced ovarian cancer: a phase I-II trial. Bramwell VH; Crowther D; O'Malley S; Swindell R; Johnson R; Cooper EH; Thatcher N; Howell A Cancer Treat Rep; 1985 Apr; 69(4):409-16. PubMed ID: 3995511 [TBL] [Abstract][Full Text] [Related]
35. Phase I study to determine the safety and pharmacokinetics of oral administration of TAS-102 in patients with solid tumors. Hong DS; Abbruzzese JL; Bogaard K; Lassere Y; Fukushima M; Mita A; Kuwata K; Hoff PM Cancer; 2006 Sep; 107(6):1383-90. PubMed ID: 16902987 [TBL] [Abstract][Full Text] [Related]
36. Pediatric phase I trial and pharmacokinetic study of the platelet-derived growth factor (PDGF) receptor pathway inhibitor SU101. Adamson PC; Blaney SM; Widemann BC; Kitchen B; Murphy RF; Hannah AL; Cropp GF; Patel M; Gillespie AF; Whitcomb PG; Balis FM Cancer Chemother Pharmacol; 2004 Jun; 53(6):482-8. PubMed ID: 14999430 [TBL] [Abstract][Full Text] [Related]